The Role of Tumor Suppressor DLC-1: Far From Clear

Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng*, Dong-Sheng Pei*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 7 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).

Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria.

Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1.

Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.

Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [896 - 901]
Pages: 6
DOI: 10.2174/1871520616666160907142754
Price: $65

Article Metrics

PDF: 54